Clinic Roundup
Otonomy Inc., of San Diego, presented positive data from a Phase Ib study of OTO-104, its lead candidate, in patients with Meniere's disease. The data suggested patients treated with OTO-104 experienced clinically meaningful reductions in vertigo frequency and improvements in tinnitus compared to placebo.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.